Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis

(2013) Nelson Watts et al.   Endocrine Practice

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

(2012) M. Shiraki et al.   OSTEOPOROSIS INTERNATIONAL

Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density

(2011) Gloria Bachmann et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin: A gem from the genome leads to bone-building antibodies

(2010) Chris Paszty et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Management of osteoporosis in postmenopausal women

(2010) &NA;   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis

(2008) Bess Dawson-Hughes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM